Listed

YPF Sociedad Anonima: Form 20-F for the period ended Dec 31, 2023

Filed with the SEC on Apr 25, 2024 and accepted by EDGAR at Apr 25, 2024, 16:43 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2023-01-01 to 2023-12-31$17.31bnifrs-full:Revenue
Cost of revenue12 months2023-01-01 to 2023-12-31$13.85bnifrs-full:CostOfSales
Gross profit12 months2023-01-01 to 2023-12-31$3.46bnifrs-full:GrossProfit
Operating income12 months2023-01-01 to 2023-12-31−$1.25bnifrs-full:ProfitLossFromOperatingActivities
Income tax12 months2023-01-01 to 2023-12-31$1.02bnifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2023-01-01 to 2023-12-31−$1.31bnifrs-full:ProfitLossAttributableToOwnersOfParent
Diluted EPS12 months2023-01-01 to 2023-12-31−$3.35ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2023-01-01 to 2023-12-31−$3.35ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2023-01-01 to 2023-12-31$5.91bnifrs-full:CashFlowsFromUsedInOperatingActivities
Cash and equivalentsAt period end2023-12-31$1.12bnifrs-full:CashAndCashEquivalents
Current assetsAt period end2023-12-31$4.43bnifrs-full:CurrentAssets
Total assetsAt period end2023-12-31$25.04bnifrs-full:Assets
Current liabilitiesAt period end2023-12-31$4.92bnifrs-full:CurrentLiabilities
Total liabilitiesAt period end2023-12-31$15.98bnifrs-full:Liabilities
Shareholders' equityAt period end2023-12-31$8.95bnifrs-full:EquityAttributableToOwnersOfParent
Shares outstandingAt period end2023-12-31393,312,793 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001193125-24-114066. Last ingested by Listed: Nov 6, 2026, 12:48 ET. Listed shows no prices and gives no investment advice.